



Ref: FOIA Reference 2021/22-642

Date: 25th April 2022

Email foi@uhnm.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 15th March 2022 requesting information under the Freedom of Information Act (2000) regarding Oesophageal and Gastric Cancer.

The University Hospitals of North Midlands Trust is committed to the Freedom of Information Act 2000.

However, the NHS is facing unprecedented challenges relating to the coronavirus (COVID-19) pandemic at the current time. Understandably, our resources have been diverted to support our front-line colleagues who are working tremendously hard to provide care for our patients, and to those in need of our services.

We strive to be transparent and to work with an open culture. But at this time, whilst care of our patients and the safety of our staff takes precedent, it is likely that responses to some requests for information will be delayed. We apologise for this position in advance, and will endeavour to provide you with as much information as we can, as soon as we are able.

The Information Commissioners Office has recognised the current situation in the NHS.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I am researching the incidence and treatment of oesophageal and gastric cancer. I would greatly appreciate if you could answer the following questions.

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- **CAPOX (Capecitabine with Oxaliplatin)**
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

A1 See below -Information for 1.12.21 to 28.2.22

- CAPOX (Capecitabine with Oxaliplatin) = 19
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) = 6
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) = 0

- Any other systemic anti-cancer therapy = 40
 - Carboplatin + Paclitaxel (weekly) + RT
 - Docetaxel 75mg/m² (21 day) UGI
 - E(Carbo)X (Epirubicin, Carboplatin, Capecitabine)
 - ECX (Epirubicin, Cisplatin and Capecitabine)
 - Paclitaxel weekly
 - FLOT (Fluorouracil+ Leucovorin+ Oxaliplatin+ docetaxel)
 - HCarboX (Carbo + Capecitabine + Trastuzumab IV (Kanjinti))
 - HGX (Capecitabine + Cisplatin + Trastuzumab IV (Kanjinti))
 - HOX (Capecitabine+Oxaliplatin+Trastuzumab IV (Kanjinti))
 - Irinotecan + Modified DeGramont
 - Irinotecan + Capecitabine
 - Palliative care only (ICD10 C15 or C16) = 6

Q2 How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with?

- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**
- **Nivolumab monotherapy**
- **Nivolumab and Ipilimumab**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 0
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) - 21
- Nivolumab monotherapy - 0
- Nivolumab and Ipilimumab - 0
- Any other systemic anti-cancer therapy - 29
 - Regimens listed in Q1 above
 - Palliative care only (ICD10 C15) <5

Q3 Of the Oesophageal Cancer patients (from Q2) treated with Pembrolizumab in the past 3 months, how many patients were treated for?

- **Oesophageal adenocarcinoma**
- **Oesophageal squamous cell carcinoma**

A3 See below:

- Oesophageal adenocarcinoma = 0
- Oesophageal squamous cell carcinoma = 0

Q4 How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with?

- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**
- **Nivolumab monotherapy**
- **Nivolumab and Ipilimumab**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) = 0
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) = <5
- Nivolumab monotherapy = 0
- Nivolumab and Ipilimumab = 0
- Any other systemic anti-cancer therapy = 0

Q5 Of the advanced/metastatic oesophageal cancer patients (from Q4) treated in the past 3 months, how many patients were treated for?

- **Advanced/metastatic oesophageal adenocarcinoma**
- **Advanced/metastatic oesophageal squamous cell carcinoma**

A5 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Advanced/metastatic oesophageal adenocarcinoma =<5
- Advanced/metastatic oesophageal squamous cell carcinoma = 0

Q6 Does your Trust participate in any active clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part?

A6 No Clinical Trials

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



University Hospitals
of North Midlands
NHS Trust

Jean Lehnert
Data, Security & Protection Manager

